Skip to main content
. 2022 May 30;10(6):875. doi: 10.3390/vaccines10060875

Figure 4.

Figure 4

Preferential binding of E4 mAb. Competition peptide ELISA revealed that addition of MS2-HMVGSTKWN as a binding competitor of E4 mAb did not change the binding potential to the VD4 peptide, whereas addition of the linear VD4 peptide reduced binding of the E4 mAb to the bait VD4 peptide.